
    
      This is a single-center,open-labelï¼Œdose-escalating phase I clinical trial in healthy 18 to 60
      years of age, inclusive, who are in good health and meet all eligibility criteria. This
      clinical trial is designed to assess the safety, reactogenicity and immunogenicity of
      Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) manufactured by Beijing
      Institute of Biotechnology and CanSino Biologics Inc.One hundred and eight subjects will be
      enrolled into one of three cohorts and will receive an intramuscular (IM) injection of
      experimental vaccine or placebo on Days 1 in the deltoid muscle.
    
  